Patent ID: 7279162

Claim:
Broadly reactive opsonophagocytic bactericidal immunoglobulin for treating a pathogenic coagulase-negative Staphylococcus infection, obtained by the process comprising: a) obtaining an immunoglobulin source chosen from at least one of serum, plasma, immunoglobulin pool, whole blood, and tissue or cells that produce or contain antibodies; and b) screening the immunoglobulin source to identify immunoglobulin that exhibits a high degree of binding to a TCA extract of serotype II Staphylococcus epidermidis by a high Optical Density of greater than 1 in an enzyme-linked immunosorbent assay (ELISA) which Optical Density has been correlated to an opsonophagocytic bactericidal activity of greater than or equal to 90% against a serotype II Staphylococcus epidermidis, such that the identified immunoglobulin is broadly reactive against Staphylococcus epidermidis serotypes I, II, and III, exhibits a high degree of binding to a TCA extract of serotype II Staphylococcus epidermidis by a high Optical Density of greater than 1 in an ELISA, has opsonophagocytic bactericidal activity of greater than or equal to 90% against a serotype II Staphylococcus epidermidis , and is for treating a pathogenic coagulase-negative staphylococcal infection.